These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26730841)

  • 21. Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational Studies.
    Werdan K; Perings S; Köster R; Kelm M; Meinertz T; Stöckl G; Müller-Werdan U
    Cardiology; 2016; 135(3):141-150. PubMed ID: 27333284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
    Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
    Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
    Vellopoulou K; Kourlaba G; Maniadakis N; Vardas P
    Int J Cardiol; 2016 May; 211():105-11. PubMed ID: 26994453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
    Arnold SV; McGuire DK; Spertus JA; Tang F; Yue P; Inzucchi SE; Belardinelli L; Chaitman BR; Kosiborod M
    Am Heart J; 2015 Oct; 170(4):753-759.e2. PubMed ID: 26386799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.
    Werdan K; Ebelt H; Nuding S; Höpfner F; Stöckl G; Müller-Werdan U
    Adv Ther; 2015 Feb; 32(2):120-37. PubMed ID: 25687888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
    Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
    Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial.
    Mehta PK; Sharma S; Minissian M; Harsch MR; Martinson M; Nyman JA; Shaw LJ; Bairey Merz CN; Wenger NK
    J Womens Health (Larchmt); 2019 May; 28(5):573-582. PubMed ID: 30888919
    [No Abstract]   [Full Text] [Related]  

  • 28. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
    Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
    J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
    Kohn CG; Parker MW; Limone BL; Coleman CI
    Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study.
    Olympios C; Stafylas P; Dermitzakis A; Efthimiadis I; Gardikiotis A; Kakouros S; Lampropoulos S; Barbetseas J; Sourgounis A; On Behalf Of Ranger Investigators
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541898
    [No Abstract]   [Full Text] [Related]  

  • 31. Ranolazine: A Contemporary Review.
    Rayner-Hartley E; Sedlak T
    J Am Heart Assoc; 2016 Mar; 5(3):e003196. PubMed ID: 26979079
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
    Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
    Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranolazine for the treatment of refractory angina in a veterans population.
    Greene RS; Rangel RM; Edwards KL; Chastain LM; Brouse SD; Alvarez CA; Collins LJ; Brilakis ES; Banerjee S
    Cardiovasc Revasc Med; 2012; 13(2):141.e1-5. PubMed ID: 21856249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
    Arnold SV; McGuire DK; Spertus JA; Li Y; Yue P; Ben-Yehuda O; Belardinelli L; Jones PG; Olmsted A; Chaitman BR; Kosiborod M
    Am Heart J; 2014 Oct; 168(4):457-465.e2. PubMed ID: 25262254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic management of chronic stable angina.
    Dixit D; Kimborowicz K
    JAAPA; 2015 Jun; 28(6):. PubMed ID: 25989429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
    Ling H; Packard KA; Burns TL; Hilleman DE
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Triple antianginal combinations in the treatment of elderly and senile patients with stable angina].
    Kanorskii SG; Smolenskaya NV
    Ter Arkh; 2016; 88(12):33-40. PubMed ID: 28139557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
    Koren MJ; Crager MR; Sweeney M
    J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina.
    Tamargo J; Lopez-Sendon J
    Future Cardiol; 2022 Mar; 18(3):235-251. PubMed ID: 34841884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
    Fanaroff AC; James SK; Weisz G; Prather K; Anstrom KJ; Mark DB; Ben-Yehuda O; Alexander KP; Stone GW; Ohman EM
    J Am Coll Cardiol; 2017 May; 69(18):2304-2313. PubMed ID: 28473136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.